Miguel Ángel M. C.
- Country
- Spain
- Department
- Endocrinology and Nutrition
Research Overview
- Phase 3 Randomized Double‑Masked Placebo‑Controlled Study of Subcutaneous Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Eneboparatide (AZP-3601) Efficacy and Safety in Chronic Hypoparathyroidism Patients
- Evaluation of Crinecerfont (NBI-74788) Efficacy and Safety in Adults with Classic Congenital Adrenal Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 31 of 139 partner sites.
Specializations
Endocrine Disorders
This investigator specializes in treating complex endocrine system disorders, with particular emphasis on parathyroid dysfunction and adrenal gland conditions.
- Chronic Hypoparathyroidism
- Endogenous Cushing Syndrome
- Classic Congenital Adrenal Hyperplasia
The investigator focuses on evaluating novel therapeutic approaches for managing hormone-related disorders and their associated complications.
Hormone Regulation
The investigator's work centers on hormonal balance restoration and metabolic regulation through innovative therapeutic interventions.
- Calcium Homeostasis
- Glucocorticoid Management
- Adrenal Steroid Control
Their research encompasses the evaluation of treatments aimed at optimizing hormone levels while minimizing therapeutic side effects.
Treatment Innovation
The investigator explores novel therapeutic compounds for treating rare and challenging endocrine conditions.
- Eneboparatide Applications
- Relacorilant Development
- Crinecerfont Studies
Their work includes assessment of long-term safety profiles and efficacy of emerging endocrine treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.